XML 93 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Information - General (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Net product sales, cost of product sales and gross profit by product      
Number of operating segments | segment 1    
Total revenues $ 1,936.3 $ 1,685.5 $ 1,483.3
Cost of sales 151.6 122.5 108.1
Gross profit 1,784.7 1,563.0 1,375.2
Tyvaso      
Net product sales, cost of product sales and gross profit by product      
Total revenues 873.0 607.5 483.3
Cost of sales 53.5 26.8 24.5
Gross profit 819.5 580.7 458.8
Remodulin      
Net product sales, cost of product sales and gross profit by product      
Total revenues 500.2 513.7 516.7
Cost of sales 34.0 37.9 23.2
Gross profit 466.2 475.8 493.5
Orenitram      
Net product sales, cost of product sales and gross profit by product      
Total revenues 325.1 306.1 293.1
Cost of sales 22.4 19.7 18.7
Gross profit 302.7 286.4 274.4
Unituxin      
Net product sales, cost of product sales and gross profit by product      
Total revenues 182.9 202.3 122.9
Cost of sales 13.1 14.2 12.6
Gross profit 169.8 188.1 110.3
Adcirca      
Net product sales, cost of product sales and gross profit by product      
Total revenues 41.3 55.9 67.3
Cost of sales 17.8 23.9 29.1
Gross profit 23.5 32.0 38.2
Other      
Net product sales, cost of product sales and gross profit by product      
Total revenues 13.8 0.0 0.0
Cost of sales 10.8 0.0 0.0
Gross profit $ 3.0 $ 0.0 $ 0.0